See more : ANAP Inc. (3189.T) Income Statement Analysis – Financial Results
Complete financial analysis of Willow Biosciences Inc. (CANSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Willow Biosciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Proton Motor Power Systems PLC (P6K0.DE) Income Statement Analysis – Financial Results
- B3 S.A. – Brasil, Bolsa, Balcão (BOLSY) Income Statement Analysis – Financial Results
- Heads UP Ventures Limited (HEADSUP.NS) Income Statement Analysis – Financial Results
- Gores Guggenheim, Inc. (GGPIW) Income Statement Analysis – Financial Results
- Terilogy Holdings Corporation (5133.T) Income Statement Analysis – Financial Results
Willow Biosciences Inc. (CANSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.willowbio.com
About Willow Biosciences Inc.
Willow Biosciences Inc., a biotechnology company, develops, produces, and sells plant derived ingredients for consumer care, food and beverage, and pharmaceutical product industries in Canada. The company also produces cannabidiol, cannabigerol, and varin cannabinoids, such as cannabigerovarin, cannabidivarin, and tetrahydrocannabivarin. Willow Biosciences Inc. was incorporated in 1981 and is headquartered in Calgary, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.17M | 821.00K | 133.00K | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.83M | 7.47M | 11.53M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -659.00K | -6.65M | -11.40M | 10.00K | 4.58K | 16.91K | 0.00 | 0.00 | 0.00 | -116.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -56.23% | -810.23% | -8,571.43% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 6.80M | 7.47M | 11.51M | 7.26M | 2.67M | 387.48K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.60M | 8.29M | 7.79M | 6.42M | 8.24M | 961.60K | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 887.93K | 2.00M | 1.01M | 1.98M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 420.00K | 808.00K | 817.00K | 0.00 | 0.00 | 588.31K | 0.00 | 31.30K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 89.13K | 76.39K | 36.47K | 87.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.29K | 7.10K |
| SG&A | 6.02M | 9.10M | 8.60M | 6.42M | 8.24M | 1.55M | 628.86K | 873.74K | 721.12K | 925.69K | 1.04M | 625.29K | 928.26K | 977.07K | 2.08M | 1.04M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 2.29K | 7.10K |
| Other Expenses | 1.54M | 0.00 | -22.00K | 0.00 | 0.00 | 0.00 | 6.61K | 30.89K | 20.08K | 60.32K | 75.13K | 50.00K | 0.00 | 3.51K | 93.90K | -84.32K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Cost & Expenses | 14.35M | 19.22M | 23.31M | 16.86M | 13.08M | 1.66M | 628.86K | 873.74K | 721.12K | 925.80K | 1.04M | 626.08K | 929.43K | 979.54K | 2.08M | 1.05M | 2.07M | 420.83K | 442.64K | 193.66K | 83.25K | 70.10K | 165.87K | 179.97K | 114.44K | 202.12K |
| Interest Income | 267.00K | 300.00K | 414.00K | 155.00K | 112.90K | 0.00 | 0.00 | 0.00 | 2.00 | 115.00 | 238.00 | 43.00 | 1.89K | 7.35K | 1.77K | 17.60K | 14.03K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.56K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 142.00K | 26.00K | 27.00K | 40.00K | 48.14K | 0.00 | 21.96K | 2.26K | 0.00 | 0.00 | 1.78K | 11.41K | 28.14K | 1.28K | 1.68K | 1.48K | 1.30K | 234.00 | 248.00 | 24.13K | 126.51K | 0.00 | 0.00 | 3.19K | 0.00 | 0.00 |
| Depreciation & Amortization | 1.83M | 2.65M | 3.19M | 3.18M | 2.17M | 46.39K | 38.38K | 30.18K | 609.49K | 116.00 | 382.00 | 787.00 | 1.17K | 2.48K | 3.73K | 3.87K | 1.03K | 0.00 | 0.00 | 0.00 | 192.73K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -11.63M | -15.45M | -2.92M | -30.72M | -43.93M | -1.60M | -1.52M | -1.07M | -4.37M | -865.26K | -962.89K | -625.25K | -951.54K | -969.72K | -1.98M | -1.11M | -2.07M | -420.83K | -442.64K | -193.66K | 13.12K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| EBITDA Ratio | -992.06% | -1,882.34% | -14,712.78% | -135,090.00% | -235,507.88% | -9,449.38% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.18M | -18.39M | -23.33M | -23.06M | -46.15M | -1.64M | -622.25K | -873.74K | -721.12K | -925.80K | -1.04M | -626.08K | -954.60K | -980.82K | -2.08M | -1.05M | -2.07M | -420.83K | -442.64K | -193.66K | -179.62K | -70.10K | -165.87K | -179.97K | -114.44K | -202.12K |
| Operating Income Ratio | -1,124.74% | -2,240.32% | -17,541.35% | -230,610.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 148.00K | 3.63M | 17.19M | -10.89M | 561.00K | 0.00 | -931.67K | -1.46M | -85.05K | 60.43K | -348.54K | -1.17M | -462.51K | -2.35M | -1.13M | -313.85K | 25.48K | -234.00 | -248.00 | 0.00 | -96.37K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -13.03M | -14.76M | -6.14M | -33.95M | -46.15M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.33M | -3.21M | -1.36M | -2.05M | -421.06K | -442.89K | 0.00 | -275.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -1,112.12% | -1,797.93% | -4,616.54% | -339,460.00% | -1,006,696.42% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -5.00K | 53.00K | 27.00K | 40.00K | -1.58M | -114.75K | -9.81K | 2.26K | -2.00 | 60.32K | 76.90K | 11.41K | 28.14K | -118.00K | -157.00K | -211.04K | -394.90K | -16.65K | -52.54K | 217.79K | 30.14K | 70.21K | 163.31K | 183.16K | 114.44K | 202.12K |
| Net Income | -13.03M | -14.81M | -6.14M | -33.95M | -44.57M | -1.64M | -1.86M | -2.33M | -1.31M | -865.37K | -1.39M | -1.80M | -1.42M | -3.22M | -3.06M | -1.15M | -1.65M | -404.41K | -390.35K | -217.79K | -306.13K | -70.21K | -163.31K | -183.16K | -114.44K | -202.12K |
| Net Income Ratio | -1,111.69% | -1,804.38% | -4,616.54% | -339,460.00% | -972,220.55% | -9,723.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -97.47 | -17.50 |
| EPS Diluted | -0.10 | -0.12 | -0.05 | -0.41 | -0.62 | -0.75 | -2.58 | -8.37 | -9.72 | -10.53 | -31.15 | -128.95 | -106.73 | -267.54 | -310.63 | -177.90 | -347.50 | -118.01 | -158.36 | -126.04 | -300.12 | -59.80 | -139.10 | -156.01 | -96.98 | -17.50 |
| Weighted Avg Shares Out | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.17K | 11.55K |
| Weighted Avg Shares Out (Dil) | 124.24M | 123.66M | 119.99M | 81.99M | 72.07M | 2.19M | 721.07K | 278.32K | 134.77K | 82.21K | 44.53K | 13.96K | 13.28K | 12.02K | 9.84K | 6.48K | 4.76K | 3.43K | 2.47K | 1.73K | 1.02K | 1.17K | 1.17K | 1.17K | 1.18K | 11.55K |
Willow Biosciences completes R&D to produce ursodeoxycholic acid
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) said it has successfully completed research and development on its program to produce ursodeoxycholic acid (UDCA), an active pharmaceutical ingredient (API) used in nutraceutical and pharmaceutical products. "Our proprietary BioOxi platform on which we are commercially...
WILLOW ANNOUNCES SUCCESSFUL COMPLETION OF R&D PROGRAM ON COST-EFFECTIVE, SUSTAINABLY PRODUCED UDCA
Company's BioOxi™ Platform solves for selective C-H hydroxylation, one of the "Holy Grails" of chemistry BioOxi is broadly applicable to manufacturing of intermediates and active pharmaceutical ingredients, particularly for steroid applications SUNNYVALE, Calif. , Sept. 6, 2023 /PRNewswire/ - Willow...
Willow Biosciences files patent application for process to produce much cheaper corticosteroids
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) told investors it has filed a patent application for a process it has developed to produce corticosteroids much more cheaply by utilizing its BioOxi platform. The global market for corticosteroids, which are broadly used as...
WILLOW ANNOUNCES FILING OF PATENT APPLICATION FOR PROCESS TO PRODUCE CORTICOSTEROIDS AT SIGNFICANTLY REDUCED COST
Company's BioOxi™-based process reduces number of steps and associated costs of corticosteroids manufacturing by up to two-thirds SUNNYVALE, Calif. , Aug. 30, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of...
Willow Biosciences appoints advisor to review opportunities as part of commercial focus on BioOxi platform
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) announced it has engaged an advisor to assist it with a review of opportunities to enhance value for its shareholders and unlock its intellectual property portfolio. The biotech company said the move follows its transition...
WILLOW BIOSCIENCES ANNOUNCES COMMERCIAL TRANSITION AND FOCUS ON BIOOXI PLATFORM
Announces commercial focus on BioOxiTM bio-oxidation platform as part of targeted alignment on nearer-term and larger revenue opportunities Reduces number of board members as part of geographic transition as a San Francisco Bay Area-based biotech company SUNNYVALE, Calif. , Aug. 24,...
Willow Biosciences shares take off on biopharma manufacturing collaboration announcement
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF)' Canadian-listed shares had added more than 23% in the early afternoon on Monday after it announced that it is collaborating with an unnamed Nasdaq-listed biopharmaceutical company to develop new sustainable manufacturing routes to key intermediates and...
Midday stock movers: Hecla, Willow Bioscience, Gorilla Tech, Palo Alto, Tesla, XPeng and more
Hecla stock drops after Lucky Friday mine collapse Hecla Mining stock dropped just over 9% in Monday's trade as it warned that a collapsed shaft at the Lucky Friday mine, in Idaho, will dent production volumes and trigger higher mining...
Willow Biosciences announces collaboration with Nasdaq-listed biopharma
Willow Biosciences Inc (TSX:WLLW, OTCQB:CANSF) has announced a collaboration with an unnamed Nasdaq-listed biopharma company to develop new sustainable manufacturing routes to key intermediates and active pharmaceutical ingredients. The company said the initial program will focus on the feasibility of developing...
WILLOW ANNOUNCES COLLABORATION WITH A LEADING INNOVATIVE BIOPHARMACEUTICAL COMPANY TO DEVELOP SUSTAINABLE INTERMEDIATES AND ACTIVE PHARMACEUTICAL INGREDIENTS
SUNNYVALE, Calif. , Aug. 21, 2023 /PRNewswire/ - Willow Biosciences Inc. ("Willow") (TSX: WLLW) (OTCQB: CANSF), a leading biotechnology company focused on revolutionizing industrial manufacturing of pure, consistent and sustainable functional ingredients, today announced a collaboration with a Nasdaq-listed biopharma company...
Source: https://incomestatements.info
Category: Stock Reports